Start here if you're new
what it is
Janux is a small biotech trying to turn your immune system into a more precise cancer-fighting weapon.
how it gets paid
Last year Janux Therapeutics made $10M in revenue. PSMA-targeted TRACTr program was the main engine at $4.0M, or 40% of sales.
why growth slowed
Revenue fell 5.6% last year. The number that mattered was n/a operating margin.
what just happened
The key takeaway is simple: Janux lost $1.28 per share in fiscal 2024 while annual revenue stayed around $10 million.
At a glance
B+ balance sheet — decent shape, but not bulletproof
-$1.28 fy2024 eps est
$11M fy2024 rev est
n/a operating margin
1.4 beta
xvary composite: 37/100 — weak
What they do
Janux is a small biotech trying to turn your immune system into a more precise cancer-fighting weapon.
Most tiny biotechs get one shot. Janux has 2 drug platforms, TRACTr and TRACIr, and 2 TRACTr candidates already in clinical trials. Tumor-activated immunotherapies (drugs designed to switch on near tumors) → more targeted cancer treatment → so what: if the safety profile holds, your upside comes from making harsh immunotherapy look more usable.
How they make money
$10M
annual revenue · their business grew -5.6% last year
PSMA-targeted TRACTr program
$4.0M
EGFR-targeted TRACTr program
$3.5M
TRACIr platform work
$1.5M
Other preclinical pipeline activity
$1.0M
The products that matter
partner-funded development work
research collaborations
$10M annual revenue
This is the whole current revenue line. It helps fund the science, but it does not explain an ~$826M equity value on its own.
current revenue
lead clinical program
JANX007
stock-driving asset
This page does not show commercial revenue from JANX007 because there is none yet. The market is still assigning most of the story to the possibility that this program works.
main catalyst
pipeline optionality
clinical platform
$12–$35 trading range
That range tells you how hard sentiment swings when a pipeline has promise but not proof. Optionality helps. It does not replace diversification.
second shot
Key numbers
-$1.28
fy2024 eps est
$11M
fy2024 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $20M (2% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for JANX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The key takeaway is simple: Janux lost $1.28 per share in fiscal 2024 while annual revenue stayed around $10 million.
This is what a clinical-stage biotech looks like before product revenue shows up. EPS improved from -$1.32 in 2023 to -$1.28 in 2024, but the business still ran at a n/a operating margin.
$10M
revenue
$1.28
fy2024 eps
n/a
operating margin
the number that mattered
The number that mattered was n/a operating margin, because it tells you Janux is still a clinical asset portfolio, not a self-funding business.
source: EDGAR annual figures and company data, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is JANX007 failing to earn confidence before financing risk matters again.
med
JANX007 underwhelms
This is still a lead-program story. If JANX007 disappoints, the market has very little current business to fall back on because annual revenue is only $10M.
With no P/E and no product sales, disappointment gets priced through credibility, not earnings revisions.
med
cash burn turns into dilution pressure
Clinical companies live on calendar math. If timelines slip while revenue stays around $10M, new capital becomes the next question and existing holders usually pay for it.
The catch: a B+ balance sheet helps, but it does not make a pre-commercial biotech self-funding.
med
volatility stays brutal even without bad science
JANX has 1.4 beta, 5 / 100 price stability, and a $12–$35 52-week range. That is what a catalyst stock looks like when conviction changes faster than fundamentals.
You can be directionally right on the science and still get punished by timing.
With just $10M of annual revenue and no earnings, almost the entire ~$826M valuation rests on pipeline credibility. If confidence in JANX007 slips, there is no mature operating business underneath to catch the stock.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next company update
Use the next update to judge whether management is moving JANX007 closer to proof or just buying more time. With a stock like this, timing matters almost as much as data.
trend
JANX007 conviction
This is the trend that matters. If investor confidence improves here, an ~$826M valuation can make sense. If it fades, the stock starts looking like a $10M revenue company again.
risk
financing pressure
Watch for any sign that the market starts focusing more on funding than on science. That is when a catalyst story turns into a dilution story.
metric
revenue reality check
Track the $10M revenue base for what it is: background funding, not thesis support. If the valuation case is working, it will come from better proof, not a bigger current sales line.
Analyst rankings
short-term outlook
mixed
target data is thin. in human-speak: there is no clean wall street consensus to lean on here.
risk profile
volatile
A 1.4 beta and 5 / 100 price stability say this clearly. You should expect wider swings than the average stock.
chart momentum
catalyst-led
This chart follows trial confidence more than neat technical patterns. If you want smooth trend lines, you own the wrong sector.
earnings predictability
40 / 100
The business model is still changing shape. That makes earnings less informative and program updates more important.
source: institutional data
Institutional activity
institutional ownership data for JANX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$13
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive